Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast can...
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
About this item
Full title
Author / Creator
Vahdat, Linda T. , Schmid, Peter , Forero-Torres, Andres , Blackwell, Kimberly , Telli, Melinda L. , Melisko, Michelle , Möbus, Volker , Cortes, Javier , Montero, Alberto J. , Ma, Cynthia , Nanda, Rita , Wright, Gail S. , He, Yi , Hawthorne, Thomas , Bagley, Rebecca G. , Halim, Abdel-Baset , Turner, Christopher D. and Yardley, Denise A.
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
The METRIC study (NCT#0199733) explored a novel antibody–drug conjugate, glembatumumab vedotin (GV), targeting gpNMB that is overexpressed in ~40% of patients with triple-negative breast cancer (TNBC) and associated with poor prognosis. The study was a randomized, open-label, phase 2b study that evaluated progression-free survival (PFS) of GV compa...
Alternative Titles
Full title
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
Authors, Artists and Contributors
Author / Creator
Schmid, Peter
Forero-Torres, Andres
Blackwell, Kimberly
Telli, Melinda L.
Melisko, Michelle
Möbus, Volker
Cortes, Javier
Montero, Alberto J.
Ma, Cynthia
Nanda, Rita
Wright, Gail S.
He, Yi
Hawthorne, Thomas
Bagley, Rebecca G.
Halim, Abdel-Baset
Turner, Christopher D.
Yardley, Denise A.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_17180d15d53a444b97cb83ce78fb7480
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_17180d15d53a444b97cb83ce78fb7480
Other Identifiers
ISSN
2374-4677
E-ISSN
2374-4677
DOI
10.1038/s41523-021-00244-6
